Overview

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Status:
Completed

Trial end date:
2018-11-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine descriptively the efficacy of CNTO 1959 in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Antibodies, Monoclonal